PTC299 for Treatment of Neurofibromatosis Type 2

Sponsor

PTC Therapeutics (Industry)

Overall Status

Terminated

CT.gov ID

NCT00911248

Collaborator

United States Department of Defense (U.S. Fed)

Enrollment

Location

Arm

Actual Duration (Months)

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Formation of new blood vessels (angiogenesis) is important for tumor growth in neurofibromatosis type 2 (NF2). It is known that tumors make a protein called vascular endothelial growth factor (VEGF) and there are higher levels of VEGF in the tumors and blood of many patients with NF2. VEGF stimulates the formation of blood vessels that supply the tumor with nutrients and oxygen. PTC299 is an oral drug that has been shown to decrease production of VEGF in animal models of human cancer. In these animal models, oral PTC299 administration decreases VEGF levels in the tumor and in the bloodstream, decreases blood vessel numbers in the tumor, and significantly slows or halts tumor growth. Safety studies in research animals indicate good tolerability at doses and drug levels that are higher than those planned for the clinical studies. Results from Phase 1a studies in healthy volunteers indicate that PTC299 achieves levels of PTC299 in the bloodstream that are known to be active in animal models of human tumor. This Phase 2 study is designed to test the hypothesis that PTC299 will be tolerable and will show evidence of VEGF reduction, antitumor activity, and hearing improvement when administered orally to patients with NF2.

Condition or Disease	Intervention/Treatment	Phase
Neurofibromatosis 2	Drug: PTC299	Phase 2

Detailed Description

The study will be conducted in 2 stages. In Stage 1 of the study, 11 patients will receive daily treatment with PTC299 administered at 100 mg/dose twice per day for up to 1 year or until tumor progression. If no subject responds with tumor shrinkage or an improvement in hearing, then the study will be stopped. If ≥1 out of 11 subjects respond, then the study will proceed to Stage 2 to enroll an additional 14 subjects for a total of 25 subjects.

Study Design

Study Type:

Interventional

Actual Enrollment :

11 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 2 Study to Assess the Efficacy, Safety, and Pharmacodynamic Activity of PTC299 in Patients With Neurofibromatosis Type 2

Actual Study Start Date :

Jul 31, 2009

Actual Primary Completion Date :

Mar 31, 2012

Actual Study Completion Date :

Mar 31, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: PTC299 PTC299 administered at 100 mg/dose twice per day	Drug: PTC299 PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression

Arm

Intervention/Treatment

Experimental: PTC299

PTC299 administered at 100 mg/dose twice per day

Drug: PTC299

PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression

Outcome Measures

Primary Outcome Measures

To assess the effects of PTC299 on tumor volume and/or word recognition in patients with NF2. [48 weeks]

Secondary Outcome Measures

To assess the effects of PTC299 on pure tone thresholds, brainstem auditory evoked responses (BAERs), and otoacoustic emissions (OAEs) in patients with NF2 [48 weeks]
To determine if PTC299 alters the perception of tinnitus [48 weeks]
To evaluate the effects of PTC299 on tumor blood flow [48 weeks]
To assess the effects of PTC299 on concentrations of circulating angiogenic factors or cytokines [48 weeks]
To describe the PTC299 safety profile [48 weeks]
To evaluate compliance with PTC299 treatment [48 weeks]
To assess PTC299 plasma exposure over time [48 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥18 years
Diagnosis of NF2
Presence of vestibular schwannomas
Evidence of progressive increase in vestibular schwannoma size or worsening hearing loss due to vestibular schwannoma
Adequate functional status (Karnofsky Performance Score ≥60)
Adequate bone marrow, liver, kidney function
If sexually active, willingness to use effective barrier or medical contraception
For women of childbearing potential, no pregnancy or breast-feeding
Discontinuation of other therapies (except corticosteroids) for the treatment of NF2 and resolution of any acute toxic effects of prior therapies
Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions
Willingness to provide informed consent

Exclusion Criteria:

Uncontrolled hypertension, major bleeding, HIV infection, or recent acute cardiovascular event
Prior exposure to another anti-angiogenic therapy (eg, bevacizumab, sunitinib)